Item 8.01 Other Events

On November 9, 2009, the High Court of Ireland approved the reduction of the $3,910,472,012 share premium created when Warner Chilcott plc became the ultimate holding company of the Warner Chilcott group in August 2009. This reduction will create distributable reserves of approximately $3.9 billion, which can be used to fund distributions (including the payment of cash dividends) to shareholders or share buy-backs in future periods. The reduction became effective upon the filing of the order of the High Court of Ireland with the Irish Companies Registration Office on November 12, 2009.

Item 9.01 Financial Statements and Exhibits

(a) Financial statements of businesses acquired

The audited combined balance sheets of P&G Pharmaceuticals as of June 30, 2009 and 2008, and the related combined statements of income, equity and cash flows for each of the three years in the period ended June 30, 2009 are filed as Exhibit 99.1 and incorporated by reference into this Item 9.01. In addition, the unaudited combined balance sheets as of September 30, 2009 and June 30, 2009 and the related combined statements of income, equity and cash flows for each of the three month periods ended September 30, 2009 and 2008 are filed as Exhibit 99.2 and incorporated by reference into this Item 9.01.

(b) Pro forma financial information

The required unaudited pro forma financial information with respect to the PGP Acquisition is filed as an Exhibit 99.3 and incorporated by reference into this Item 9.01.

(d) Exhibits

Exhibit
No. Description

23.1 Consent of Deloitte & Touche LLP

99.1 P&G Pharmaceuticals audited combined financial statements

99.2 P&G Pharmaceuticals unaudited combined financial statements

99.3 Unaudited pro forma financial information

---